Purpose Of The Study: Empirical studies on the determinants of bridge employment have often neglected the fact that some retirees may be unsuccessful in finding a bridge job. We present an integrative framework that emphasizes socioeconomic factors, health status, social context, and psychological factors to explain why some people fully retired after career exit, some participated in bridge jobs, while others unsuccessfully searched for one.
Design And Methods: Using Dutch panel data for 1,221 retirees, we estimated a multinomial logit model to explain participation in, and unsuccessful searches for, bridge employment.
Results: About 1 in 4 retirees participated in bridge employment after retirement, while 7% searched unsuccessfully for such work. Particularly those who experienced involuntary career exit were found to have a higher probability of being unsuccessful at finding bridge employment.
Implications: The current study provides evidence for the impact of the social context on postretirement work and suggests a cumulative disadvantage in the work domain in later life.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1093/geront/gnu182 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Managing Major Life Changes: An Exploratory Study Using the Bridges Transitions Framework to Help Foster Youth Prepare for Discharge.
Children (Basel)
December 2024
School of Social Work, University of St. Thomas, St. Paul, MN 55105, USA.
Background: Adolescents in foster care endure frequent disruptive transitions, often culminating in discharge to independent living rather than reunification or adoption. Former foster youth fare poorly once on their own, with high rates of homelessness and social disconnection. This study explored the use of the Bridges Transitions Framework near the end of placement to help youth cope with the transition to adulthood.
View Article and Find Full Text PDFEstimated Long-Term Dietary Exposure to Cadmium from Consumption of Spinach in the United States: A Probabilistic Assessment.
Food Chem Toxicol
January 2025
Western Growers Association.
As part of the U.S. Food and Drug Administration's (FDA's) Closer to Zero initiative, a toxicological reference value (TRV) for oral dietary exposure to Cd was established.
View Article and Find Full Text PDFImproving Social Determinants of Health via the Workplace.
Am J Health Promot
January 2025
Health Promotion Research Center, Department of Health Systems and Population Health, School of Public Health, University of Washington, Seattle, WA, USA.
: Social determinants of health (SDOH), such as food security and healthcare access, are key to maintaining and improving health. Publicly funded safety-net programs, such as Medicaid and the Supplemental Nutrition Assistance Program, address SDOH. Many low-wage employees are program-eligible, but there are substantial participation gaps.
View Article and Find Full Text PDFCost-effectiveness of Dual Hypothermic Oxygenated Machine Perfusion Versus Static Cold Storage in DCD Liver Transplantation.
Transplantation
February 2025
Division of HPB and Transplant Surgery, Department of Surgery, Erasmus MC Transplant Institute, University Medical Center Rotterdam, Rotterdam, the Netherlands.
Background: Ex situ machine perfusion of the donor liver, such as dual hypothermic oxygenated machine perfusion (DHOPE), is increasingly used in liver transplantation. Although DHOPE reduces ischemia/reperfusion-related complications after liver transplantation, data on cost-effectiveness are lacking. Our objective was to evaluate the cost-effectiveness of DHOPE in donation after circulatory death (DCD) liver transplantation.
View Article and Find Full Text PDFThe Role of Intravenous Selexipag in Managing PAH and Bridging Gaps in Oral Treatment: A Narrative Review.
Ther Clin Risk Manag
January 2025
Departments of Medicine and Cardiology, Westchester Medical Center and New York Medical College, Valhalla, NY, USA.
Pulmonary arterial hypertension (PAH) is a rare and potentially fatal condition characterized by progressive increases in blood pressure in the arteries of the lungs. Oral selexipag, approved by the Food and Drug Administration (FDA) in 2015 for the treatment of PAH, targets prostacyclin receptors on pulmonary arterial vascular smooth muscle and endothelial cells to improve blood flow through the lungs and reduce pulmonary vascular resistance. Oral selexipag is effective, but may be discontinued due to factors like side effects, emergency conditions, or inability to take oral medication, potentially leading to severe adverse events, such as rebound pulmonary hypertension and right heart failure.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!